In the latest issue of European Pharmaceutical Review, our CEO, Dominik Schumacher, and our CSO, Jonas Helma-Smets, discuss the advancements in the field since the approval of the first ADC generation and explain how Tubulis’ innovative conjugation platforms enable the creation of uniquely matched ADCs to address current shortcomings like narrow therapeutic windows, off-target toxicities and limitations for certain indications.
Read the full article here.